Reduced RANBP9 expression is associated with poor prognosis in colorectal cancer patients

Wu, Guangbin; Li, Ji; Qin, Chunzhi

doi:10.21037/tcr.2019.10.24

Cited by 5 publications

(6 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nowadays, the application of effective tumor biomarkers has become one of hot issues in the field of cancer research, and is associated with the patient’s quality of life and survival outcomes ( 12 , 13 ). THY1 has been identified over-expressed on the cytoplasmic membrane in several cell types.…”

Section: Discussionmentioning

confidence: 99%

Multiple roles of THY1 in gastric cancer based on data mining

Hu¹,

Jin²,

Zhou³

et al. 2020

Transl Cancer Res TCR

View full text Add to dashboard Cite

Background THY1 (CD90) is a heavily N-glycosylated, glycophosphatidylinositol (GPI) anchored cell surface protein, which has been implicated in several cancers. But, the specific mechanism and function of the THY1 gene remains unclear in gastric cancer (GC). Methods To investigate the function of THY1 in GC and illustrate the potential mechanism, TCGA and FIREBROWSE were used to detect the THY1expression. GEPIA2 and Kaplan-Meier Plotter showed significant correlation among THY1 mRNA level, TNM stage and survival probability of GC patients. Results THY1 was up-regulated apparently in GC in contrast to normal tissues and linked to TNM stage. GC patients with higher THY1 expression displayed lower overall survival (OS), first progression (FP) and post-progression survival (PPS). In vitro experiments showed that knockdown of THY1 suppressed proliferation, migration while increased autophagy level in GC cells. Immune factors may interact with THY1mRNA in GC and THY1 was found significantly linked with Tregs. Conclusions Our findings indicate that higher THY1 level is link to poor prognosis of GC patients. THY1may as well be used as a marker molecule for evaluating the tumor microenvironment status of GC patients and a target for immunotherapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Multiple roles of THY1 in gastric cancer based on data mining

Hu¹,

Jin²,

Zhou³

et al. 2020

Transl Cancer Res TCR

View full text Add to dashboard Cite

show abstract

“…Eleven (11) of those entries were expected CTLH complex members, clearly indicating that the immunoprecipitation by 3xHA worked efficiently (Table 2). We repeated the same purging process for the V5-immunoprecipitated proteomic list in comparison with the three negative control groups (V5-immunoprecipitated from WT, Ig-immunoprecipitated from LysMBP9X mice, and Ig-immunoprecipitated from LysMBP9 WT controls).…”

Section: Ranbp9-v5 Can Be Efficiently Immunoprecipitated From Bp9v5 M...mentioning

confidence: 94%

“…While the absence of RanBP9 causes perinatal lethality, occasional RanBP9-deficient mouse survivors on a mixed genetic background display reduced body size and severe sterility both in males and females 7 . Expression of RanBP9 increases in several types of malignancies 1, [8][9][10][11] . Due to the weakening of DNA repair in RanBP9deficient cells, RanBP9 has been put forward as a potential target of therapy in nonsmall cell lung cancer 9,10,12 .…”

Section: Introductionmentioning

confidence: 99%

Anin vivo“turning model” reveals new RanBP9 interactions in lung macrophages

Kajimura,

Tessari,

Orlacchio

et al. 2024

Preprint

View full text Add to dashboard Cite

The biological functions of the scaffold protein Ran Binding Protein 9 (RanBP9) remain elusive in macrophages or any other cell type where this protein is expressed together with its CTLH (C-terminal to LisH) complex partners. We have engineered a new mouse model, named RanBP9-TurnX, where RanBP9 fused to three copies of the HA tag (RanBP9-3xHA) can be turned into RanBP9-V5 tagged upon Cre-mediated recombination. We created this model to enable stringent biochemical studies at cell type specific level throughout the entire organism. Here, we have used this tool crossed with LysM-Cre transgenic mice to identify RanBP9 interactions in lung macrophages. We show that RanBP9-V5 and RanBP9-3xHA can be both co-immunoprecipitated with the known members of the CTLH complex from the same whole lung lysates. However, more than ninety percent of the proteins pulled down by RanBP9-V5 differ from those pulled-down by RanBP9-HA. The lung RanBP9-V5 associated proteome includes previously unknown interactions with macrophage-specific proteins as well as with players of the innate immune response, DNA damage response, metabolism, and mitochondrial function. This work provides the first lung specific RanBP9-associated interactome in physiological conditions and reveals that RanBP9 and the CTLH complex could be key regulators of macrophage bioenergetics and immune functions.

show abstract

“…Previous studies have identified tumor size, clinical stage, and tumor indexes as the critical prognostic factors for colorectal cancer (2)(3)(4)(5). Lately, KPS, number of brain metastases, the albumin-to-globulin ratio, fibrinogen-toalbumin ratio and other hematological indicators are proved to related to overall survival in patients with colorectal cancer.…”

Section: Original Articlementioning

confidence: 99%

Platelet to lymphocyte ratio as a prognostic factor in patients with advanced colorectal cancer undergoing palliative treatment

Gui¹,

Wang²,

Luo³

et al. 2020

Ann Palliat Med

View full text Add to dashboard Cite

Background: Our study aims to investigate the level of platelet to lymphocyte ratio (PLR) and determine its prognostic value in patients with advanced colorectal cancer undergoing palliative treatment.Methods: One hundred and fifty-two patients with advanced colorectal cancer confirmed in our hospital from January 2013 to January 2018 were selected as study participants. The boundary-value of PLR was determined by receiver operating characteristics (ROC) curves. Furthermore, the relationship between PLR and clinical characteristics of patients with advanced colorectal cancer was analyzed. Next, the prognostic factors affecting the survival time were analyzed by Kaplan-Meier single factor survival analysis and Cox multivariate regression model.Results: According to the ROC curve, the optimal critical value of PLR was 207.29. Patients were divided into high PLR (n=73) and low PLR (n=79) groups. The median survival time was 68.0 (24.5, 296.5) days for the high PLR group, and 124 (34, 438) days for the low PLR group and differences between the groups were statistically significant (P<0.05). Both groups had similar demographic features, namely gender, age, Eastern Cooperative Oncology Group (ECOG) score, and several metastasis sites (P>0.05). Albumin and hemoglobin levels were found to be negatively correlated to PLR (P<0.05). Cox multivariate regression model results showed that PLR, albumin, and ECOG score were independent prognostic factors (P<0.05).Conclusions: This study demonstrated that PLR is an independent prognostic factor of survival time, with good predictive value, in patients with advanced colorectal cancer undergoing palliative treatment. High PLR was significantly correlated to reduced survival rates, while low PLR was associated with better longterm survival rates.

show abstract

Reduced RANBP9 expression is associated with poor prognosis in colorectal cancer patients

Cited by 5 publications

References 34 publications

Multiple roles of THY1 in gastric cancer based on data mining

Multiple roles of THY1 in gastric cancer based on data mining

Anin vivo“turning model” reveals new RanBP9 interactions in lung macrophages

Platelet to lymphocyte ratio as a prognostic factor in patients with advanced colorectal cancer undergoing palliative treatment

Contact Info

Product

Resources

About